24-24 April 2023
Qmed+
REGISTER NOW
keyboard_arrow_left See all news

Recent News

10 Jan, 2023 /
Qosina
Qosina introduces Irradiate to Order service for single-use bioprocess components
Qosina introduces an Irradiate to Order service for its single-use bioprocess component ...
09 Jan, 2023 /
Qosina
Qosina Announces Partnership with ILC Dover and Expanded Portfolio of Liquid Bag Chambers
Qosina announces a partnership with ILC Dover, a leader in the innovative design and pro...
05 Jan, 2023 /
Life Science Outsourcing, Inc.
Life Science Outsourcing Completes Acquisition of J-Pac Medical
Expands into biomaterials and diagnostics end-markets, broadens service offerings, and s...
04 Jan, 2023 /
Qosina
Qosina introduces AseptiQuik® G DC Series Connectors
Qosina announces the addition of the AseptiQuik® G DC Series connectors to its extensiv...
17 Nov, 2022 /
PTI Engineered Plastics, Inc.
PTI Engineered Plastics Receives MedAccred® Plastics Continuing Accreditation
PTI Engineered Plastics recognized for its commitment to continual improvement in medica...
Cirtec Medical
/ 21 Dec, 2020
keyboard_arrow_left See all news

Cirtec Medical Announces Acquisition of NovelCath

Minneapolis, MN—December 17, 2020 — Cirtec Medical Corporation, a strategic outsourcing partner of complex medical devices including minimally invasive and active implantable devices, today announced that it has acquired NovelCath, a vertically integrated manufacturer of highly engineered catheter delivery systems based in Brooklyn Park, MN.

"We are excited to add NovelCath's capabilities to our portfolio.” stated Brian Highley, Cirtec CEO. “We continually look for ways to expand our manufacturing capabilities and enhance our value-added services to customers. This acquisition is a natural fit for us.”

NovelCath specializes in minimally invasive interventional delivery systems ranging from structural heart to electrophysiology and neurovascular applications. They are experienced in design collaboration, development, manufacture of highly engineered braided and coiled reinforced catheter shafts, complex steerable and multi-directional sheath designs, and microcatheters.

This acquisition further strengthens Cirtec's structural heart business which includes design and development, vertical integration of components, and full-device-assembly for both implantable devices and complex delivery systems. The NovelCath facility located adjacent to Cirtec's Minneapolis headquarters, will become Cirtec's Center of Excellence for Catheters and Delivery Systems, and will include expanded Nitinol processing, catheter development, assembly, packaging, and volume manufacturing capabilities with a path to Costa Rica production.

Tim Maes, NovelCath CEO and one of four founding partners commented, “We are thrilled to be joining Cirtec Medical. This is a tremendous opportunity for our organization and employees to continue our growth trajectory by joining and contributing to the growth of a recognized leader in the medical device space.”

About Cirtec Medical

Cirtec Medical is a vertically integrated, full-service outsource partner providing end-to-end product design, development, and manufacturing of Class III and II medical devices and components. We specialize in today's most advanced product technologies including, neuromodulation, implantable drug delivery, cardiac rhythm management, ventricular assist, structural heart, and minimally invasive systems. Cirtec has a global footprint with facilities in Brooklyn Park, MN; Chandler, AZ; Enfield, CT; Los Gatos, CA; Lowell, MA; Alajuela, Costa Rica; and Birkenfeld, Germany.

Processing. Please wait.
Loading...